Dr Tanja Mueller

Publications

Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study : a retrospective population-based cohort study

Mahmoud Fatema, Mueller Tanja, Mullen Alexander, Sainsbury Christopher, Rushworth Gordon F, Kurdi Amanj

Diabetes, Obesity and Metabolism (2024)

https://doi.org/10.1111/dom.15584

Risk of winter hospitalisation and death from acute respiratory infections in Scotland : national retrospective cohort study

Shi Ting, Millington Tristan, Robertson Chris, Jeffrey Karen, Katikireddi Srinivasa Vittal, McCowan Colin, Simpson Colin R, Woolford Lana, Daines Luke, Kerr Steven, Swallow Ben, Fagbamigbe Adeniyi, Vallejos Catalina A, Weatherill David, Jayacodi Sandra, Marsh Kimberley, McMenamin Jim, Rudan Igor, Ritchie Sir Lewis Duthie, Mueller Tanja, Kurdi Amanj, Sheikh Sir Aziz

Journal of the Royal Society of Medicine (2024)

https://doi.org/10.1177/01410768231223584

Analysis of the use of antibiotics by AWaRe categories during the COVID-19 pandemic in hospitals across Scotland : a national population-based study

Proud Euan, Mueller Tanja, Gronkowski Karen, Kurdi Amanj, Platt Niketa, Morrison Aidan, Bennie Marion, Malcolm William

European Journal of Hospital Pharmacy (2024)

https://doi.org/10.1136/ejhpharm-2023-003874

Involving patients and clinicians in the design of wireframes for cancer medicines electronic patient reported outcome measures in clinical care : mixed methods study

Dunlop Emma, Ferguson Aimee, Mueller Tanja, Baillie Kelly, Laskey Jennifer, Clarke Julie, Kurdi Amanj, Wales Ann, Connolly Thomas, Bennie Marion

JMIR Formative Research Vol 7 (2023)

https://doi.org/10.2196/48296

Heterogeneity after harmonisation : a retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries

Komen J J, Hunt N B, Pottegård A, Hjemdahl P, Wettermark B, Olesen M, Bennie M, Mueller T, Carragher R, Karlstad Ø, Kjerpeseth L J, Klungel O H, Forslund T

Pharmacoepidemiology and Drug Safety Vol 32, pp. 1223-1232 (2023)

https://doi.org/10.1002/pds.5650

Data resource profile: : the Hospital Electronic Prescribing and Medicines Administration (HEPMA) national data collection in Scotland

Mueller Tanja, Proud Euan, Kurdi Amanj, Jarvis Lynne, Reid Kat, McTaggart Stuart, Bennie Marion

International Journal of Population Data Science Vol 8 (2023)

https://doi.org/10.23889/ijpds.v8i6.2182

More publications

Teaching

I teach content across all years of the MPharm degree course, with a focus on information gathering and interpretation; research methods; and communication skills. I also teach critical appraisal, research methods including study designs and data analysis/statistics, and other transferrable skills on the MSc Clinical Pharmacy course. Furthermore, I am actively engaged in supervising undergraduate (MPharm) as well as postgraduate taught (MSc Clin Pharm) and research (MPhil, PhD) students.

My main areas of interest are Public Health, and the intersection of medical/pharmaceutical topics and wider societal issues. In my teaching, I aim to spark interest in research among students, and strive to develop their skills holistically.

Professional Activities

40th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (Event)

Peer reviewer

3/2024

Careers Fayre

Contributor

15/2/2024

BMC Geriatrics (Journal)

Peer reviewer

2024

BMJ Open (Journal)

Peer reviewer

2024

International Journal of Population Data Science (Journal)

Peer reviewer

2024

Research in Social and Administrative Pharmacy (Journal)

Peer reviewer

2024

More professional activities

Projects

Profiling and assessing medicines use in pregnancy in Scotland: a population-based, whole system prescribing approach using routine data from clinical care

Mueller, Tanja (Principal Investigator) Kurdi, Amanj (Co-investigator)

01-Jan-2023 - 30-Jan-2027

PHS Medicines Programme

Kurdi, Amanj (Principal Investigator) Mueller, Tanja (Co-investigator)

01-Jan-2023 - 30-Jan-2028

22/145 Systems Engineering Innovation hubs for Multiple longterm Conditions - Devlopment phase

Maier, Anja (Principal Investigator) Connolly, Patricia (Co-investigator) Gray, Louise (Co-investigator) Inns, Tom (Co-investigator) Kurdi, Amanj (Co-investigator) Maguire, Roma (Co-investigator) Mehnen, Jorn (Co-investigator) Michie, Craig (Co-investigator) Mueller, Tanja (Co-investigator) Picanco Rodrigues, Vinicius (Co-investigator) Tachtatzis, Christos (Co-investigator) Whitfield, Ian (Co-investigator)

01-Jan-2023 - 31-Jan-2024

Cancer Medicines Outcomes Programme Interim 23-24

Bennie, Marion (Principal Investigator) Kurdi, Amanj (Co-investigator) Kavanagh, Kimberley (Co-investigator) Mueller, Tanja (Co-investigator) Dunlop, Emma (Principal Investigator) Fontes, Pedro (Researcher) Csoban, Tunde (Researcher)

Continuation of funding for the CMOP programme for 23-24

01-Jan-2023 - 31-Jan-2024

Big projects, little community benefit? How low carbon pilot projects help to tackle fuel and transport poverty in island communities

Calvillo Munoz, Christian (Principal Investigator) Fonseca, Liliana (Co-investigator) Mueller, Tanja (Co-investigator)

27-Jan-2023 - 26-Jan-2023

Factors associated with the prescribing of direct acting oral anticoagulant drugs and the impact of the COVID-19 pandemic on the prescribing of these drugs: A Scoping Review

Abunimeh, Hanan Nabeel (Post Grad Student) Kurdi, Amanj (Academic) Mueller, Tanja (Principal Investigator)

Direct-Acting Oral Anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, and rivaroxaban – have emerged and are being used as alternatives to vitamin k antagonists for the prevention and treatment of different cardiovascular conditions (1,2). Since the DOACs first approval in the UK in 2008 (3), they have become the preferred choice for anticoagulation, because of their documented non-inferior efficacy and safety in large randomized prospective trials and real-world observational studies, and because of their much more convenience to use (4-6). With the rapid uptake of DOACs, prescribers are faced with increasingly complex decisions relating to appropriate agent and appropriate dose to be prescribed (7). This review will explore and provide an overview of the factors influencing the prescribing of DOACs in general.

02-Jan-2023 - 29-Jan-2023

More projects